Relapsed Multiple Myeloma - Pipeline Review, H1 2014
M2 - 1 hr 36 mins ago
Research and Markets (http://www.researchandmarkets.com/research/hg9nqn/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Kyowa Hakko Kirin - Sanofi - Eli Lilly and Company - GlaxoSmithKline - Genentech - Piramal Enterprises - Prolexys - Millennium - Novartis - Astellas - Exelixis - Celgene - Threshold - Synta - Acceleron - Altor BioScience - Arno - Stemline - Noxxon - Acetylon - Pharma - Janssen - AbbVie - Oncopeptides - Senhwa Biosciences For more information visit http://www.researchandmarkets.com/research/hg...d_multiple
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - 2 hrs 27 mins ago
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell
Jim Cramer's 'Mad Money' Recap: Forget Washington and Stay the Course
at The Street - Wed Jun 11, 7:20PM CDT
Nothing turns buyers into sellers faster than wrangling in Washington, Cramer says.
Is AbbVie's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 11, 5:05PM CDT
AbbVie is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs in 2013. Big drug companies, such as AbbVie, Johnson & Johnson , and Amgen , offer...
Final Glance: Pharmaceuticals companies
AP - Wed Jun 11, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Wed Jun 11, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Is Medtronic a Buy? What Analyst Day Revealed
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Jun 11, 4:05PM CDT
Medtronic 's June 6 analyst day was by no means light fare, as the company crammed quite a bit of information into more than seven hours. While action-oriented investors are likely disappointed that management's commentary would seem to...
Aduro BioTech Secures $55 Million Series C Financing
Business Wire - Wed Jun 11, 3:00PM CDT
Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced the closing of a $55 million Series C financing. New investor Johnson & Johnson Development Corporation (JJDC) joined the Morningside group and other new and existing investors in the transaction.
Midday Glance: Pharmaceuticals companies
AP - Wed Jun 11, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Wed Jun 11, 12:20PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are down at 1 p.m.:
Stage Set for FIFA World Cup: 2 Sponsors in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 11:36AM CDT
As the stage is set for the FIFA World Cup 2014 kickoff , 32 participating teams along with 22 corporate sponsors are fine-tuning their plans to make this mega event a grand success.
Early Glance: Pharmaceuticals companies
AP - Wed Jun 11, 9:35AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Wed Jun 11, 9:35AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are down at 10 a.m.:
2014 Report on the International Infusion Pumps & Accessories (Diabetes, Chemotherapy, Nutrition, Pain Management) Market - Forecasts to 2018
M2 - Wed Jun 11, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cg9l76/infusion_pumps) has announced the addition of the "2014 Report on the International Infusion Pumps & Accessories (Diabetes, Chemotherapy, Nutrition, Pain Management) Market - Forecasts to 2018" report to their offering. Infusion pumps and accessories have evolved from regular pumps to modern, automated, integrated, and flexible pumps to meet patient compliance requirements and also provide cost-effective treatment. The safety and quality of infusion pumps and accessories have also gained greater importance in the healthcare market over the years. In this report, the global infusion pump and accessories market is broadly segmented by product, application, and end user. The market, depending on the type of product, is further segmented into devices (pumps) and accessories/disposables. The accessories/disposables are further subdivided into dedicated disposables and non-dedicated disposables. On the basis of the application area, the market is categorized into diabetes, chemotherapy/oncology, gastroenterology, hematology, analgesia/pain management, pediatrics/neonatology, and others. Based on end users, the market is divided into hospitals, home care, and others. Over the past few years, the infusion pumps and accessories market has witnessed a stable growth rate. By 2018, the market is expected to grow at a CAGR of 5.7% from 2013 to 2018 to reach $9,427 million. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insight 4 Market Dynamics 5 Infusion Pumps & Accessories Market, By Product 6 Infusion Pumps And Accessories Market, By Application 7 Infusion Pumps And Accessories Market, By End User 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - B. Braun Melsungen Ag - Baxter International Inc. - Carefusion Corporation - Fresenius Se & Co. Kgaa - Hospira, Inc. - Johnson & Johnson - Medtronic, Inc. - Moog Inc. - Smiths Medical - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/cg...sion_pumps
Jazz Pharmaceuticals Names Russell J. Cox To Position Of Chief Operating Officer
PR Newswire Europe - Wed Jun 11, 12:44AM CDT
Jazz Pharmaceuticals plc today announced the appointment of Russell J. Cox to the newly created position of chief operating officer (COO). Mr. Cox, who joined Jazz Pharmaceuticals in July 2010, most recently served as executive vice president and chief commercial officer at the company. He will continue to report to Bruce Cozadd, chairman and chief executive officer, and will now have global responsibility for the commercial, research and development (R&D) and technical operations organizations.
Sabine Dandiguian Honoured as HBA Luminary by the Healthcare Businesswomen's Association (HBA)
PR Newswire Europe - Tue Jun 10, 10:13PM CDT
HAMBURG, Germany, May 13, 2014 /PRNewswire/ --
Pharmacyclics' Imbruvica Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 5:45PM CDT
Pharmacyclics (PCYC) announced that the FDA will review its Imbruvica sNDA on a priority basis.
Dendreon's CEO Departs at Critical Juncture - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 4:20PM CDT
Dendreon (DNDN) is now faced with a difficult time with its chief executive officer John H. Johnson deciding to step down on personal reasons.